Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Huawei uvádza riešenie AI Practice LAB (AIPL), ktoré stanovuje novú paradigmu pre rozvoj talentov v oblasti „vzdelávanie + umelá inteligencia"
- Greenberg Traurig Named Among BTI's 'Most Feared Law Firms in Litigation' for 2027
- La linterna de clip más vendida de Olight evoluciona: la serie Oclip 2 gira y se inclina
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →